Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(2):157-160
DOI: 10.5428/pcar20180221
Pharmaceutical care of anticoagulation on a patient with acute ischemic stroke plus atrial fibrillation
1. HUA ZhiHui(a zhihui19998@126.com)
2. LIU Jing(a )
3. FAN LinLin(a )
4. et al(a lmf1312230904@163.com)
Welcome to PCAR! You are the number 215 reader of this article!
Please cite this article as:
HUA ZhiHui,LIU Jing,FAN LinLin,et al,. Pharmaceutical care of anticoagulation on a patient with acute ischemic stroke plus atrial fibrillation[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(2): 157-160.
References:
1. WANG DanDan,CHEN ShengYun,ZHAO XingQuan.Different severity of acute ischemic stroke and intravenous thrombolysis[J].Chin J Stroke,2016,11(10):870-874.In Chinese with English abstract.
2. WANG YiLong,LIAO XiaoLing,ZHAO XingQuan,et al.Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR)[J].Stroke,2011,42(6):1658-1664.
3. WANG YiLong,XU Jie,ZHAO XingQuan,et al.Association of hypertension with stroke recurrence depends on ischemic stroke subtype[J].Stroke,2013,44(5):1232-1237.
4. Marini C,De Santis F,Sacco S,et al.Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study[J].Stroke,2005,36(6):1115-1119.
5. Hart R G,Pearce L A,Aguilar M I.Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J].Ann Intern Med,2007,146(12):857-867.
6. WU XueLan,TAO TingTing,XU ChuangGui,et al.Rational use and control of adverse drug reactions of omerprazole[J].Chin Pharm Aff,2014,28(7):805-808.In Chinese with English abstract.
7. GU YinMing,WEI Meng,SONG ShaSha,et al.Effects of azithromycin on the pharmacokinetics and pharmacodynamics of oral warfarin in rats[J].Prog Pharm Sci,2010,34(3):125-130.In Chinese with English abstract.
8. Neurology Branch of Chinese Medical Association,Cerebrovascular Disease Group,Neurology Branch of Chinese Medical Association.Guidelines for the diagnosis and treatment of acute ischemic stroke in China(2014)[J].Chin J Neurol,2015,48(4): 246-257.In Chinese.
9. Writing Group of Expert Consensus on the Diagnosis and Treatment of Atrial Fibrillation in Elderly Population,Geriatrics Branch of Chinese Medical Association,Editorial Board of Chinese Journal of Geriatrics.Expert consensus on the management of non valvular atrial fibrillation in elderly population (2016)[J].Chin J Geriatr,2016,35(9):915-928.In Chinese.
10. Cardiovasology Branch of Chinese Medical Association,Committee of Cardio-cerebral-vascular Disease,Gerontology Society of China.Chinese expert consensus on warfarin anticoagulant therapy[J].Chin J Intern Med,2013,52(1):76-82.In Chinese.
11. Olesen J B,Lip G Y H,Hansen M L,et al.Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study[J].BMJ,2011,342: d124-d132.
12. CHEN KePing.What is the optimal intensity of warfarin therapy in Chinese patients with atrial fibrillation[J].Adv Cardiovasc Dis,2008,29(2):175-177.In Chinese with English abstract.
13. Prevention and Control Engineering Committee for Stroke of the National Health and Family Planning Commission.Guidelines for stroke prevention and control in Chinese patients with atrial fibrillation[S].2015: 13.In Chinese.
14. DiPiro J T,Talbert R L,Yel G C,et al.Pharmacotherapy: a pathophysiologic approach[M].9th ed.NewYork:McGraw-Hill Medical Publishing House,2014:261.
15. The International Warfarin Pharmacogentics Consortium.Estimation of the warfarin dose with clinical and pharmacogentic data[J].N Engl J Med,2009,360(8):753-764.
16. DUAN XiaoHong,DAI HaiBin.Pharmaceutical care on a patient with atrial fibrillation combined with cerebral infarction[J].Chin J Drug Appl Monit,2015,12(1):33-35.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口